J7Z Stock Overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Jazz Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$129.05 |
| 52 Week High | US$139.55 |
| 52 Week Low | US$92.40 |
| Beta | 0.44 |
| 1 Month Change | -0.58% |
| 3 Month Change | 8.58% |
| 1 Year Change | 13.55% |
| 3 Year Change | -11.49% |
| 5 Year Change | 47.49% |
| Change since IPO | 901.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| J7Z | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.1% | -2.1% | -1.3% |
| 1Y | 13.6% | -14.9% | 13.1% |
Return vs Industry: J7Z exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: J7Z matched the German Market which returned 13.3% over the past year.
Price Volatility
| J7Z volatility | |
|---|---|
| J7Z Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: J7Z has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: J7Z's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,800 | Bruce Cozadd | www.jazzpharma.com |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder.
Jazz Pharmaceuticals plc Fundamentals Summary
| J7Z fundamental statistics | |
|---|---|
| Market cap | €7.79b |
| Earnings (TTM) | €517.72m |
| Revenue (TTM) | €3.76b |
15.0x
P/E Ratio2.1x
P/S RatioIs J7Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J7Z income statement (TTM) | |
|---|---|
| Revenue | US$4.07b |
| Cost of Revenue | US$310.70m |
| Gross Profit | US$3.76b |
| Other Expenses | US$3.20b |
| Earnings | US$560.12m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.22 |
| Gross Margin | 92.36% |
| Net Profit Margin | 13.77% |
| Debt/Equity Ratio | 149.2% |
How did J7Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 07:41 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jazz Pharmaceuticals plc is covered by 49 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |
| Richard Silver | Barclays |